SYRS · Syros Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $3.76M | $2.83M | $2.95M | - | $3.89M | $6.28M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $20.53M | $21.95M | $24.66M | - | $28.28M | $29.61M | $28.76M | - | $25.76M | $33.10M |
| SG&A | $5.66M | $5.46M | $6.27M | - | $7.76M | $7.22M | $7.41M | - | $8.08M | $6.95M |
| Total Operating Expenses | $26.18M | $27.42M | $30.92M | - | $38.40M | $36.83M | $36.17M | - | $43.34M | $40.05M |
| D&A | - | - | $334.0K | - | - | - | $638.0K | - | - | - |
| Operating Income | ($26.18M) | ($27.42M) | ($30.92M) | - | ($34.64M) | ($34.00M) | ($33.21M) | - | ($39.45M) | ($33.77M) |
| Interest Expense | $1.30M | $1.38M | $1.31M | - | $1.30M | $1.28M | $1.22M | - | $1.05M | $981.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($6.40M) | ($23.33M) | ($3.71M) | - | ($40.14M) | ($36.26M) | ($23.79M) | - | ($30.25M) | ($34.48M) |
| EPS - Basic | ($0.16) | ($0.59) | ($0.10) | - | ($1.43) | ($1.30) | ($0.85) | - | ($4.14) | ($5.40) |
| EPS - Diluted | ($0.16) | ($0.59) | ($0.10) | - | ($1.43) | ($1.30) | ($3.99) | - | ($4.14) | ($5.40) |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58.27M | $78.96M | $83.52M | $139.53M | $112.22M | $115.44M | $104.77M | $167.47M | $171.53M | $59.06M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $9.65M | $7.47M | $11.35M | $11.54M | $2.85M | $6.69M | $2.79M | $6.41M | $13.02M | $6.12M |
| Current Assets | $63.93M | $84.92M | $112.20M | $144.98M | $122.52M | $152.63M | $173.64M | $211.39M | $252.31M | $91.94M |
| Total Assets | $85.00M | $106.72M | $134.73M | $168.17M | $147.79M | $180.98M | $205.32M | $244.49M | $284.73M | $126.23M |
| Current Liabilities | $28.39M | $24.52M | $37.30M | $36.68M | $28.39M | $28.38M | $23.55M | $30.78M | $38.42M | $38.93M |
| Long-term Debt | $41.08M | $40.93M | $29.71M | $34.56M | $39.41M | $40.93M | $39.12M | $40.65M | $40.51M | $33.97M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($11.12M) | ($6.35M) | $15.06M | $16.66M | $36.30M | $73.24M | $106.75M | $127.74M | $129.17M | $31.02M |
| Retained Earnings | ($756.24M) | ($749.84M) | ($726.51M) | ($722.81M) | ($658.42M) | ($618.28M) | ($582.02M) | ($558.23M) | ($553.46M) | ($523.21M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($31.10M) | - | - | - | ($36.90M) | - | - | - |
| Investing Cash Flow | - | - | ($24.64M) | - | - | - | ($25.75M) | - | - | - |
| Financing Cash Flow | - | - | ($265.0K) | - | - | - | ($53.0K) | - | - | - |
| CapEx | - | - | - | - | - | - | $235.0K | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | ($37.14M) | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -920.7% | -1200.1% | -1124.3% | - | -1014.0% | -538.1% |
| EBITDA margin | - | - | - | - | - | - | -1102.7% | - | - | - |
| Net margin | - | - | - | - | -1067.1% | -1279.8% | -805.3% | - | -777.5% | -549.4% |
| Free cash flow margin | - | - | - | - | - | - | -1257.1% | - | - | - |
| FCF / Net income | - | - | - | - | - | - | 1.56 | - | - | - |
| R&D / Revenue | - | - | - | - | 751.7% | 1045.1% | 973.6% | - | 662.0% | 527.4% |
| SG&A / Revenue | - | - | - | - | 206.4% | 255.0% | 250.7% | - | 207.6% | 110.7% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.5% | -21.9% | -2.8% | - | -27.2% | -20.0% | -11.6% | - | -10.6% | -27.3% |
| Return on equity | 57.5% | 367.2% | -24.6% | - | -110.6% | -49.5% | -22.3% | - | -23.4% | -111.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.25 | 3.46 | 3.01 | 3.95 | 4.31 | 5.38 | 7.37 | 6.87 | 6.57 | 2.36 |
| Quick ratio | 2.25 | 3.46 | 3.01 | 3.95 | 4.31 | 5.38 | 7.37 | 6.87 | 6.57 | 2.36 |
| Cash ratio | 2.05 | 3.22 | 2.24 | 3.80 | 3.95 | 4.07 | 4.45 | 5.44 | 4.46 | 1.52 |
| Leverage | ||||||||||
| Debt / Equity | -3.69 | -6.44 | 1.97 | 2.07 | 1.09 | 0.56 | 0.37 | 0.32 | 0.31 | 1.10 |
| Debt / Assets | 0.48 | 0.38 | 0.22 | 0.21 | 0.27 | 0.23 | 0.19 | 0.17 | 0.14 | 0.27 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -20.1x | -19.8x | -23.7x | - | -26.6x | -26.6x | -27.3x | - | -37.5x | -34.4x |
| Equity multiplier | -7.64 | -16.80 | 8.95 | 10.09 | 4.07 | 2.47 | 1.92 | 1.91 | 2.20 | 4.07 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | 0.03 | 0.02 | 0.01 | - | 0.01 | 0.05 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 13.8x | - | 3.0x | 1.2x | 0.2x | - | 0.5x | 19.5x |
| P / S | - | - | - | - | 29.4x | 31.0x | 5.7x | - | 15.6x | 96.4x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | -3.3% | -54.9% | -46.0% | - | -31.7% | 21.6% |
| Revenue CAGR (3y) | - | - | - | - | -0.6% | -3.9% | 7.5% | - | 86.5% | 132.4% |
| Revenue CAGR (5y) | - | - | - | - | 55.6% | 47.9% | 21.8% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 24.4% | 19.4% | 6.9% | - | 12.2% | -0.7% | -24.6% | - | -46.6% | -29.2% |
| Net income growth (YoY) | 84.1% | 35.7% | 84.4% | - | -32.7% | -5.2% | 5.4% | - | -16.2% | -53.3% |
| EPS growth (YoY) | 88.8% | 54.6% | 97.5% | - | 65.5% | 75.9% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | -23.2% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -85.9% | -87.0% | -71.9% | 136.1% | 70.1% | 49.9% | 21.8% | -76.1% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Syros Pharmaceuticals against the 5 most active filers in the same SIC group.